<SEC-DOCUMENT>0001140361-25-017615.txt : 20250507
<SEC-HEADER>0001140361-25-017615.hdr.sgml : 20250507
<ACCEPTANCE-DATETIME>20250507073358
ACCESSION NUMBER:		0001140361-25-017615
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20250507
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250507
DATE AS OF CHANGE:		20250507

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immunocore Holdings plc
		CENTRAL INDEX KEY:			0001671927
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39992
		FILM NUMBER:		25919303

	BUSINESS ADDRESS:	
		STREET 1:		90 PARK DRIVE
		STREET 2:		MILTON PARK, ABINGDON
		CITY:			OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RY
		BUSINESS PHONE:		01235 5430281

	MAIL ADDRESS:	
		STREET 1:		90 PARK DRIVE
		STREET 2:		MILTON PARK, ABINGDON
		CITY:			OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RY

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Immunocore Ltd
		DATE OF NAME CHANGE:	20160412
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ef20048471_8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:cef="http://xbrl.sec.gov/cef/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:imcr="http://immunocore.com./20250507" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 25.3.2.5298
         Copyright 1995 - 2025 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html"/>
</head>

<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_ecc1db2c3367422f97892b3e3fe3b170" contextRef="c20250507to20250507" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_0ac1a0787d654b5d909ba3f7b67f0b32" contextRef="c20250507to20250507">0001671927</ix:nonNumeric><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_c6eda689bea14232ab6026f85bd34936" contextRef="c20250507to20250507">00-0000000</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="imcr-20250507.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="c20250507to20250507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671927</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-07</xbrli:startDate><xbrli:endDate>2025-05-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250507to20250507_StatementClassOfStockAxis_OrdinaryShareNominalValueGBP0002PerShareMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imcr:OrdinaryShareNominalValueGBP0002PerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-07</xbrli:startDate><xbrli:endDate>2025-05-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250507to20250507_StatementClassOfStockAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-07</xbrli:startDate><xbrli:endDate>2025-05-07</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
<div style="line-height: initial;">
  <div><span style="font-size: 10pt;"> </span></div>

  <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/>
  <div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">UNITED STATES</div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">WASHINGTON, D.C. 20549</div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br/>
    </div>

    <div style="font-size: 10pt;">
      <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; color: #000000; text-align: center; margin-left: auto; margin-right: auto;"/></div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_aa2ed1e62dd441ffbea5264fa13ea5ee" contextRef="c20250507to20250507">8-K</ix:nonNumeric></div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="font-size: 10pt;">
      <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; color: #000000; text-align: center; margin-left: auto; margin-right: auto;"/></div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Pursuant to Section 13 or 15(d)</div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">of the Securities Exchange Act of 1934</div>

    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-size: 10pt;"><br/>
      </span></div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_8ec9d7f294884306834e7be27c17dc0a" contextRef="c20250507to20250507" format="ixt:date-monthname-day-year-en">May 7, 2025</ix:nonNumeric></div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br/>
    </div>

    <div style="font-size: 10pt;">
      <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; color: #000000; text-align: center; margin-left: auto; margin-right: auto;"/></div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 24pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_a784e4a95ea64e59bde367bacef7fd96" contextRef="c20250507to20250507">Immunocore Holdings plc</ix:nonNumeric><br/>
    </div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Exact name of registrant as specified in its Charter)</div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br/>
    </div>

    <div style="font-size: 10pt;">
      <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; color: #000000; text-align: center; margin-left: auto; margin-right: auto;"/></div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 33%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><span style="text-decoration: underline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_7df24f49abc94bfb8880431cd56774d7" contextRef="c20250507to20250507" format="ixt-sec:edgarprovcountryen">England and Wales</ix:nonNumeric></span><br/>
            </div>
          </td>

    <td style="width: 34%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><span style="text-decoration: underline;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_96bbc3cf5f854d0eb83147d36d4c2416" contextRef="c20250507to20250507">001-39992</ix:nonNumeric></span><br/>
            </div>
          </td>

    <td style="width: 33%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><span style="text-decoration: underline;"><span style="-sec-ix-hidden:Fact_c6eda689bea14232ab6026f85bd34936">Not Applicable</span></span><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 33%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">(State or other jurisdiction of incorporation)</div>
          </td>

    <td style="width: 34%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">(Commission File Number)</div>
          </td>

    <td style="width: 33%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">(IRS Employer Identification No.)</div>
          </td>

  </tr>


</table>
    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-size: 10pt;"><br/>
      </span></div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_6fb2b60cb0354d88bba7c65a3545e940" contextRef="c20250507to20250507">92 Park Drive</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_63c885967ef94e6e9acbb0e3bba169f2" contextRef="c20250507to20250507">Milton Park, Abingdon</ix:nonNumeric>, </div>
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_a1df8faf64e144d4b30273a0316f8701" contextRef="c20250507to20250507">Oxfordshire</ix:nonNumeric>,</div>
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCountry" id="Fact_8813a03ca49540b7a1a4e614977b25b3" contextRef="c20250507to20250507" format="ixt-sec:countrynameen">United Kingdom</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 2%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 49%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_63b6d4f8c9d94fbb99440606fee1da25" contextRef="c20250507to20250507">OX14 4RY</ix:nonNumeric><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 49%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">(Address of principal executive offices)</div>
          </td>

    <td style="width: 2%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 49%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">(Zip Code)</div>
          </td>

  </tr>


</table>
    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">+<ix:nonNumeric name="dei:CityAreaCode" id="Fact_6cf8d955604448c3beb7d9872d2debd6" contextRef="c20250507to20250507">44</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_b00d58703c65477ea456f6b922bec8b5" contextRef="c20250507to20250507">1235 438600</ix:nonNumeric></div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Registrant&#8217;s telephone number, including area code)</div>

    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-size: 10pt;"><br/>
      </span></div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Not Applicable</div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Former name or former address, if changed since last report)</div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br/>
    </div>

    <div style="font-size: 10pt;">
      <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; color: #000000; text-align: center; margin-left: auto; margin-right: auto;"/></div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
      following provisions:</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 9pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_d057cdeac33b40eda5fa5c5529236e22" contextRef="c20250507to20250507" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
          </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br/>
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 9pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_6f7a140323cc4fb2a527b2be5880438e" contextRef="c20250507to20250507" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
          </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br/>
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 9pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_64cf1fb6fd994deaac996b45a57c5f80" contextRef="c20250507to20250507" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
          </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br/>
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 9pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_519e5e39b11142a494941b20cf97541f" contextRef="c20250507to20250507" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
          </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 62.17%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Title of each class</div>
          </td>

    <td style="width: 9.15%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Trading</div>
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Symbol(s)</div>
          </td>

    <td style="width: 28.69%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Name of each exchange on which registered</div>
          </td>

  </tr>

  <tr>

    <td style="width: 62.17%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_4b1113f9c694496ba3cc7bf3d6471a38" contextRef="c20250507to20250507_StatementClassOfStockAxis_CommonStockMember">American Depositary Shares, each representing one ordinary share, nominal value &#163;0.002 per share</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 9.15%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_357d4262392d414b985164d2afb7f1ab" contextRef="c20250507to20250507_StatementClassOfStockAxis_CommonStockMember">IMCR</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 28.69%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_4a9bd6cf21cf49ee92b54ef1ec79c4c6" contextRef="c20250507to20250507_StatementClassOfStockAxis_CommonStockMember">NASDAQ</ix:nonNumeric><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 62.17%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_76b778887af648cb884153225e062dcc" contextRef="c20250507to20250507_StatementClassOfStockAxis_OrdinaryShareNominalValueGBP0002PerShareMember">Ordinary share, nominal value &#163;0.002 per share*</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 9.15%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_230b79239d4947acad3c90ba4660e297" contextRef="c20250507to20250507_StatementClassOfStockAxis_OrdinaryShareNominalValueGBP0002PerShareMember">*</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 28.69%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_8bfcc247a31b44c78a9618a5ec82ae2d" contextRef="c20250507to20250507_StatementClassOfStockAxis_OrdinaryShareNominalValueGBP0002PerShareMember">NASDAQ</ix:nonNumeric><br/>
            </div>
          </td>

  </tr>


</table>
    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-size: 10pt;"><br/>
      </span></div>

    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">* <span style="font-family: 'Times New Roman'; font-style: italic;">Not for trading, but only in connection with the listing of the American Depositary
        Shares on The Nasdaq Stock Market LLC.</span></div>

    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-size: 10pt;"><br/>
      </span></div>

    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter)
      or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</div>

    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-size: 10pt;"><br/>
      </span></div>

    <div style="text-align: right; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_099328ba678b4a6eb3cbfe0540fea9b6" contextRef="c20250507to20250507" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div>

    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-size: 10pt;"><br/>
      </span></div>

    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
      revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>

    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';"> <br/>
      </span></div>

    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">
      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/>
<div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 72pt; vertical-align: top; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 2.02.</td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Results of Operations and Financial Condition.</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: left; text-indent: 18pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">On May 7, 2025, Immunocore Holdings plc (the &#8220;Company&#8221;) issued a press release announcing its financial results for the first quarter
      ended March 31, 2025, as well as other recent corporate updates. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated by reference.</div>

    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-size: 10pt;"><br/>
      </span></div>

    <div style="text-align: left; text-indent: 18pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The information in this Item 2.02 of this Current Report on 8-K, including Exhibit 99.1 hereto, is being furnished and shall not be
      deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company&#8217;s
      filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in
      such filing.</div>

    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-size: 10pt;"><br/>
      </span></div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 90pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 9.01.</td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Financial Statements and Exhibits</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 10%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><span style="text-decoration: underline;">Exhibit No.</span></div>
          </td>

    <td style="width: 90%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><span style="text-decoration: underline;">Description</span></div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';"><a href="ef20048471_ex99-1.htm">99.1</a></div>
          </td>

    <td style="width: 90%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Press Release dated May 7, 2025.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">104</div>
          </td>

    <td style="width: 90%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Cover Page Interactive Data File (embedded within the Inline XBRL document).</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

    </div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">SIGNATURES</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by
      the undersigned hereunto duly authorized.</div>

    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-size: 10pt;"><br/>
      </span></div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 40%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="vertical-align: top; font-size: 10pt;" colspan="4">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">IMMUNOCORE HOLDINGS PLC</div>
          </td>

  </tr>

  <tr>

    <td style="width: 40%; vertical-align: middle; font-size: 10pt;">&#160;</td>

    <td style="width: 5%; vertical-align: middle; font-size: 10pt;">&#160;</td>

    <td style="vertical-align: middle; font-size: 10pt;" colspan="3">&#160;</td>

  </tr>

  <tr>

    <td style="width: 40%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Dated: May 7, 2025</div>
          </td>

    <td style="width: 5%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">By:</div>
          </td>

    <td style="vertical-align: top; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">/s/ Bahija Jallal, Ph.D.</div>
          </td>

    <td style="width: 1%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 40%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 5%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 10%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Name:</div>
          </td>

    <td style="width: 44%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Bahija Jallal, Ph.D.</div>
          </td>

    <td style="width: 1%; vertical-align: top; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 40%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 5%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 10%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Title:</div>
          </td>

    <td style="width: 44%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Chief Executive Officer</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="font-size: 10pt;">
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

  </div>

  <div><span style="font-size: 10pt;"> </span></div>

</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ef20048471_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 25.3.2.5298
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-size: 10pt;"> </font>
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div style="text-align: right;"><font style="font-weight: bold; font-size: 10pt;">Exhibit 99.1</font><font style="font-size: 10pt;"><br>
    </font></div>
  <div> <font style="font-size: 10pt;"><br>
    </font></div>
  <div>
    <div style="font-size: 10pt;"><img src="image00002.jpg"><br>
      <br>
    </div>
    <div style="text-align: center; margin-left: 3.3pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Immunocore reports first quarter financial results and provides a business update</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">KIMMTRAK<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">On track for Phase 3 TEBE-AM trial to complete enrollment in 1H 2026</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">On track for dose selection in Phase 3 PRISM-MEL-301 trial in 2H 2025</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Initial multiple ascending dose data for HIV functional cure candidate presented during oral session at CROI 2025; dose escalation ongoing</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Cash, cash equivalents and marketable securities of $837 million as of March 31, 2025</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">(<font style="font-family: 'Times New Roman';">OXFORDSHIRE, England &amp; CONSHOHOCKEN, Penn. &amp; GAITHERSBURG, Md., US</font>, May 7, 2025) <u>Immunocore Holdings
        plc (Nasdaq: IMCR) (&#8220;Immunocore&#8221; or the &#8220;Company&#8221;)</u>, a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and
      autoimmune diseases, today announced its financial results for the first quarter ended March 31, 2025, and provided a business update.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">"We are thrilled to have achieved strong revenue performance in Q1, marked by year-over-year growth of 33%. This reflects our unwavering dedication to making KIMMTRAK
      accessible to patients who need it," said <font style="font-family: 'Times New Roman'; font-weight: bold;">Bahija Jallal, Chief Executive Officer of Immunocore</font>. "In R&amp;D, we continue to be laser-focused on execution in our oncology
      franchise with three ongoing Phase 3 trials and a promising early pipeline. We are also excited to have presented the initial MAD data at CROI from our ongoing HIV trial, which, together with our progress in autoimmune, underscores the breadth of our
      platform."</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="width: 100%;" class="BRPFPageFooter">
        <div>
          <div style="font-size: 10pt;">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 33.33%;"><img src="image00003.jpg"></td>
                  <td style="width: 33.33%;"><img src="image00004.jpg"></td>
                  <td style="width: 33.33%; text-align: right; vertical-align: bottom;">
                    <div><br>
                      <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 8pt; font-family: 'Times New Roman';">Page </font><font style="font-size: 8pt;">1</font><font style="font-size: 8pt; font-family: 'Times New Roman';"> of 15 </font></div>
                    </div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      <div style="width: 100%;" class="BRPFPageHeader">
        <div><img src="image00002.jpg"></div>
      </div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>First Quarter 2025 Highlights (including post-period)</u></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Financial Results</u></div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u> <br>
      </u></div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Total net product revenue (or &#8220;net sales&#8221;) arising from the sales of KIMMTRAK<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (tebentafusp) was $93.9 million in the first quarter of 2025, an increase of
      33% over the first quarter of 2024, of which $56.6 million was generated in the United States, $32.8 million in Europe and $4.5 million in international regions.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Research &amp; development expenses for the three months ended March 31, 2025, were $56.5 million, compared to $57.5 million for the same period in 2024. Selling,
      general and administrative (SG&amp;A) expenses for the three months ended March 31, 2025, were $40.2 million, compared to $39.3 million in the same period in 2024.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Net income for the first quarter of 2025 was $5.0 million compared to a net loss of $24.4 million in the same period in 2024. The first quarter basic and diluted
      income/(loss) per share was $0.10, compared to $(0.49) for the first quarter of 2024.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Cash, cash equivalents and marketable securities at March 31, 2025, were $837.0 million.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>KIMMTRAK</u></div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u> <br>
      </u></div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">The Company&#8217;s lead product, KIMMTRAK<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (tebentafusp), is approved in 39 countries and has been launched in 26 countries globally to date
      for HLA-A*02:01 positive people with metastatic uveal melanoma (mUM). KIMMTRAK continues to be the standard of care in most markets where it is launched.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">The Company sees three key growth areas for KIMMTRAK including continued global expansion in mUM, the potential expansion into 2L+ advanced cutaneous
      melanoma (CM), and the potential expansion into adjuvant uveal melanoma.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Metastatic uveal melanoma</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z294d00edb19240daa4675c1b9f974c67" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">In the first quarter of 2025, KIMMTRAK net product sales were $93.9 million.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="z2c1a125e4d36484dbe50345897a302f1" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">Now launched in two additional countries for a total of 26 globally.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="zc791e72cc4b04c57847a84bdeb5814c7" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">13% year-over-year growth in the United States, with demand continuing to grow as outreach extends into the community setting.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="z3f28f2ec43204aef99ea4bbb93d26e74" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">Growth in Europe and in international regions driven by increased demand, new country launches, and completion of price negotiations in France and Germany.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">2L+ advanced cutaneous melanoma</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z5dfebbbb777244f8a01a21fe587a93f2" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">The Company is currently enrolling the TEBE-AM registrational Phase 3 trial and expects to complete enrollment in the first half of 2026.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter">
        <div>
          <div style="font-size: 10pt;">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 33.33%;"><img src="image00003.jpg"></td>
                  <td style="width: 33.33%;"><img src="image00004.jpg"></td>
                  <td style="width: 33.33%; text-align: right; vertical-align: bottom;">
                    <div><br>
                      <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 8pt; font-family: 'Times New Roman';">Page </font><font style="font-size: 8pt;">2</font><font style="font-size: 8pt; font-family: 'Times New Roman';"> of 15 </font></div>
                    </div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div style="width: 100%;" class="BRPFPageHeader">
        <div><img src="image00002.jpg"></div>
      </div>
    </div>
    <table cellspacing="0" cellpadding="0" id="zc11dbf5ee099492b879e250fbb80e6fe" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">The Phase 3 trial is enrolling three arms: tebentafusp monotherapy, tebentafusp in combination with pembrolizumab, and a control (investigator's choice of therapy including options such as
              investigator&#8217;s choice of clinical trials, chemotherapy, or retreatment with anti-PD1 or BRAF therapy).</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="z8cba93ea4da04005a0b9ce9ee2349424" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">There is great unmet need in second- and later-line cutaneous melanoma, with no therapy having shown an Overall Survival (OS) improvement post checkpoint inhibitors in a randomized clinical trial.
              The Company estimates that there is a potential to address up to 4,000 previously treated advanced CM patients.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Adjuvant uveal (or ocular) melanoma<br>
      <br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z9a461468aada406b99a59335afeb9493" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">The European Organisation for Research and Treatment of Cancer (EORTC) is enrolling patients in the Phase 3 Adjuvant Trial in Ocular Melanoma (ATOM).</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="z874e91c13e6d4f0daa1d3fea022168b8" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">The Company estimates that the HLA-A*02:01 high-risk adjuvant uveal melanoma patient population could be up to 1,200 patients.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>PRAME portfolio</u></div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u> <br>
      </u></div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Brenetafusp is the Company&#8217;s lead PRAME-A02 ImmTAC bispecific candidate. Brenetafusp is being evaluated in combination with nivolumab in a Phase 3
      registrational trial (PRISM-MEL-301) in patients with first-line, advanced cutaneous melanoma, and in a Phase 1/2 clinical trial as monotherapy and in combination across multiple tumor types, including ovarian cancer and non-small cell lung cancer
      (NSCLC).</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">PRISM-MEL-301 &#8211; First PRAME Phase 3 clinical trial with brenetafusp in first-line advanced cutaneous melanoma</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z6978aee288d943b9bc5b6995e8da2a9f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">The Company is enrolling patients in the registrational Phase 3 clinical trial evaluating brenetafusp + nivolumab versus a control arm of either nivolumab or nivolumab + relatlimab for HLA-A*02:01
              positive patients with first-line, advanced or metastatic cutaneous melanoma.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="z3145883a01574c9585baebeb4b182fe3" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">The trial is currently randomizing to three arms: two brenetafusp dose regimens (40 mcg and 160 mcg) and a control arm. The Company is on track for selection of the go-forward brenetafusp dose in the
              second half of 2025; this analysis will be conducted by an IDMC.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="zddf806ad2cb2430c909d368afed82550" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">Despite approved therapies, there remains a need for improved progression-free survival and overall survival, and there is the potential to address an estimated 10,000 patients.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Phase 1/2 clinical trial of brenetafusp in multiple solid tumors</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z4d52ef2d5f3845cabcdc9d66fc02564f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">The Company continues to evaluate brenetafusp in a Phase 1/2 trial in combination with non-platinum chemotherapies in platinum-resistant ovarian cancer (PROC) and with bevacizumab or with platinum
              chemotherapy in earlier lines of platinum-sensitive ovarian cancer (PSOC). In the same trial, the Company continues signal detection in metastatic non-small cell lung cancer (NSCLC) cohorts, including brenetafusp in combination with docetaxel
              and with osimertinib in earlier-line NSCLC.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter">
        <div>
          <div style="font-size: 10pt;">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 33.33%;"><img src="image00003.jpg"></td>
                  <td style="width: 33.33%;"><img src="image00004.jpg"></td>
                  <td style="width: 33.33%; text-align: right; vertical-align: bottom;">
                    <div><br>
                      <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 8pt; font-family: 'Times New Roman';">Page </font><font style="font-size: 8pt;">3</font><font style="font-size: 8pt; font-family: 'Times New Roman';"> of 15 </font></div>
                    </div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div style="width: 100%;" class="BRPFPageHeader">
        <div><img src="image00002.jpg"></div>
      </div>
    </div>
    <table cellspacing="0" cellpadding="0" id="ze0e7a15c969942c5967d6f00fd1bd709" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">The Company estimates that, across all solid tumors, the annual number of patients worldwide who test positive for HLA-A*02:01 and can potentially benefit from this program is up to 150,000.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">IMC-P115C (PRAME-A02 Half-Life Extended) &amp; IMC-T119C (PRAME-A24)<br>
      <br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zf5e01406eca248c39eab0b59325d918b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">The Company is enrolling patients in the Phase 1 dose escalation trial, in multiple solid tumors, with IMC-P115C.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="z3b1e072656644a13afeacb76cd525b26" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">IMC-P115C is the Company&#8217;s first half-life extended ImmTAC therapy &#8211; targeting the same PRAME peptide and with the same CD3 effector and TCR specificity as brenetafusp. It is designed to improve
              patient convenience by reducing the frequency of treatment administration.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>IMC-R117C (PIWIL1) for colorectal and other gastrointestinal cancers</u></div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u> <br>
      </u></div>
    <table cellspacing="0" cellpadding="0" id="zf1ab31711549420b82ff931b15d966d8" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">The Company is enrolling patients in the Phase 1/2 dose escalation trial evaluating IMC-R117C in HLA-A*02:01 positive patients with advanced solid tumors, including colorectal cancer, as a single
              agent and in combination with standards of care.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="z060b2a3c91e642a88e8cf488636e8fb4" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">PIWIL1 is believed to play a role in tumor progression and is expressed across a range of tumors, including colorectal cancer.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>ImmTAV candidates for a functional cure in infectious diseases</u></div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u> <br>
      </u></div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">The Company&#8217;s bispecific TCR technology platform has the potential to offer a new approach for the treatment of certain chronic infections and aims
      to eliminate evidence of remaining virus in circulation after the patient stops taking medication - known as a "functional cure." Two investigational candidates are in Phase 1 or Phase 1/2 trials for people living with human immunodeficiency virus
      (HIV) and people with chronic hepatitis B infection (HBV).</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Phase 1/2 trial of IMC-M113V (Gag-A02) for people living with HIV</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zcfdde70119ec4aefa72249d4a1513f8f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">The Company presented data from the initial multiple ascending dose (MAD) portion of the Phase 1/2 dose escalation trial, including 16 people living with HIV (PLWH), at the 2025 Conference on
              Retroviruses and Opportunistic Infections (CROI).</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="zc339fd4d3b26491dafcc7b88dc8eb64a" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">All doses were well tolerated and no serious adverse events or dose limiting toxicities were observed.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="zc0a7b1a7c29a44fabe806f7628c56a25" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">In the 15 evaluable PLWH, delayed viral rebound and/or viremia control at any point during the analytical treatment interruption (ATI) was observed in 0 of 5 PLWH at 60 mcg, 1 of 5 at 120 mcg, and 2
              of 5 at 300 mcg.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter">
        <div>
          <div style="font-size: 10pt;">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 33.33%;"><img src="image00003.jpg"></td>
                  <td style="width: 33.33%;"><img src="image00004.jpg"></td>
                  <td style="width: 33.33%; text-align: right; vertical-align: bottom;">
                    <div><br>
                      <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 8pt; font-family: 'Times New Roman';">Page </font><font style="font-size: 8pt;">4</font><font style="font-size: 8pt; font-family: 'Times New Roman';"> of 15 </font></div>
                    </div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div style="width: 100%;" class="BRPFPageHeader">
        <div><img src="image00002.jpg"></div>
      </div>
    </div>
    <table cellspacing="0" cellpadding="0" id="z3ff1ea9f5ab449e1958ca2c19086ef5e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">The 3 PLWH with evidence of viral control had a viral load of approximately 200 copies/mL at week 8. The historical rate for this observation is 5%<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup>. Furthermore, 2 of these 3 PLWH
              remained off ART for the entire 12-week ATI period that was pre-specified in the protocol.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="zbe6bd6843af84ac297ed26aa8925beb9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">Patient enrollment continues at higher doses in the multiple ascending dose part of the Phase 1/2 clinical trial to identify a safe and tolerable dose.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Phase 1 trial of IMC-I109V (Envelope-A02) for people living with HBV or HBV-positive hepatocellular carcinoma</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z8ee852859fec4182ac263135ff8fd532" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">The Company plans to report data from the single ascending dose portion of the trial in the second half of 2025.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Tissue-specific down modulation of the immune system for autoimmune diseases</u></div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u> <br>
      </u></div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">The key differentiator of the ImmTAAI platform is tissue-specific, down modulation of the immune system, as the candidates suppress pathogenic T
      cells via PD1 receptor agonism only when tethered to the target tissue.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">IMC-S118AI (PPI-A02) for type 1 diabetes</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zb61d561d695248cca7a7cf94abef0708" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">The Company is on track to file a CTA or investigational new drug application (IND) for IMC-S118AI (PPI x PD1) in the second half of 2025.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="z3a176ed440764501ac31ca01e825a9c4" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">IMC-S118AI is targeted specifically to the pancreatic beta-cell and intended as a disease-modifying treatment in type 1 diabetes. IMC-S118AI recognizes a peptide from pre-pro-insulin protein that is
              presented by HLA-A02 on beta cells and has a PD1 agonist effector arm.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">IMC-U120AI (CD1a) for atopic dermatitis as the initial indication - first universal program</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zc8a005458ab74e6db558098014784701" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">The Company plans to file a CTA/IND for IMC-U120AI (CD1a x PD1) in 2026.</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="z096b01a7673745cdb807e3ee9a55e1d6" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">IMC-U120AI is a non-HLA-restricted (i.e. universal for all populations) CD1a-tethered PD1 agonist ImmTAAI therapy. IMC-U120AI has a dual mechanism of action: blocking CD1a (which presents lipids)
              from activating CD1a-specific T cells and preventing HLA Class I/II (which presents peptides) from activating T cells via PD1 agonism on the T cell.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Financial Results</u></div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u> <br>
      </u></div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Basic and diluted income per share was $0.10 for the quarter ended March 31, 2025, as compared to a basic and diluted loss per share of ($0.49) for the same period in
      2024. Net income for the quarter ended March 31, 2025, was $5.0 million, as compared to a net loss of $(24.4) million for the same period in 2024.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <hr noshade="noshade" align="left" style="height: 2px; width: 20%; color: #000000; background-color: #000000; text-align: left; margin-left: 0px; margin-right: auto; border: none;">
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup>&#160;<font style="font-family: 'Times New Roman';">Gunst, J.D., Gohil, J., Li, J.Z. et al. Time to HIV viral rebound and frequency of post-treatment control
        after analytical interruption of antiretroviral therapy: an individual data-based meta-analysis of 24 prospective studies. </font><font style="font-family: 'Times New Roman'; font-style: italic;">Nat Commun</font><font style="font-family: 'Times New Roman';"> 16, 906 (2025).</font></div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-family: 'Times New Roman';"> <br>
      </font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter">
        <div>
          <div style="font-size: 10pt;">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 33.33%;"><img src="image00003.jpg"></td>
                  <td style="width: 33.33%;"><img src="image00004.jpg"></td>
                  <td style="width: 33.33%; text-align: right; vertical-align: bottom;">
                    <div><br>
                      <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 8pt; font-family: 'Times New Roman';">Page </font><font style="font-size: 8pt;">5</font><font style="font-size: 8pt; font-family: 'Times New Roman';"> of 15 </font></div>
                    </div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div style="width: 100%;" class="BRPFPageHeader">
        <div><img src="image00002.jpg"></div>
      </div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">For the first quarter ended March 31, 2025, the Company generated net product sales of $93.9 million compared to $70.3 million for the same period in 2024, due to sales
      of KIMMTRAK, of which $56.6 million was in the United States, $32.8 million (including one-time favorable revenue adjustments recorded upon completion of price negotiations in France and Germany of $6.0M) was in Europe, and $4.5 million was in the
      international regions. The increase in net product sales was due to global country expansion and increased sales volume in the United States, as we continued our commercialization efforts.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">For the first quarter ended March 31, 2025, research and development (R&amp;D) expenses were $56.5 million compared to $57.5 million for the same period in 2024.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">For the quarter ended March 31, 2025, SG&amp;A expenses were $40.2 million compared to $39.3 million for the same period in 2024.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Cash, cash equivalents and marketable securities were $837.0 million as of March 31, 2025, as compared to $820.4 million as of December 31, 2024.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">##</div>
    <div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">About ImmTAC<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> molecules for cancer</div>
      <div style="font-size: 10pt;"><br>
      </div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Immunocore&#8217;s proprietary T cell receptor (TCR) technology generates a novel class of bispecific biologics called ImmTAC (Immune mobilizing monoclonal TCRs Against
      Cancer) molecules that are designed to redirect the immune system to recognize and kill cancerous cells. ImmTAC molecules are soluble TCRs engineered to recognize intracellular cancer antigens with ultra-high affinity and selectively kill these
      cancer cells via an anti-CD3 immune-activating effector function. Based on the demonstrated mechanism of T cell infiltration into human tumors, the ImmTAC mechanism of action holds the potential to treat hematologic and solid tumors, regardless of
      mutational burden or immune infiltration, including immune &#8220;cold&#8221; low mutation rate tumors.</div>
    <div>
      <div style="font-size: 10pt;"><br>
      </div>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter">
        <div>
          <div style="font-size: 10pt;">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 33.33%;"><img src="image00003.jpg"></td>
                  <td style="width: 33.33%;"><img src="image00004.jpg"></td>
                  <td style="width: 33.33%; text-align: right; vertical-align: bottom;">
                    <div><br>
                      <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 8pt; font-family: 'Times New Roman';">Page </font><font style="font-size: 8pt;">6</font><font style="font-size: 8pt; font-family: 'Times New Roman';"> of 15 </font></div>
                    </div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div style="width: 100%;" class="BRPFPageHeader">
        <div><img src="image00002.jpg"></div>
      </div>
    </div>
    <div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">About ImmTAV molecules and infectious diseases</div>
      <div style="font-size: 10pt;"><br>
      </div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">ImmTAV (Immune mobilising monoclonal TCRs Against Virus) molecules are novel bispecifics that are designed to enable the immune system to recognize and eliminate virally
      infected cells.</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Immunocore is advancing clinical candidates to cure patients with HIV and hepatitis B virus (HBV). The Company aims to achieve sustained control of HIV after patients
      stop anti-retroviral therapy (ART), without the risk of virological relapse or onward transmission. This is known as &#8216;functional cure&#8217;. For the treatment of HBV, the Company aims to achieve sustained loss of circulating viral antigens and markers of
      viral replication after stopping medication for people living with chronic HBV.</div>
    <div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">About ImmTAAI molecules and autoimmune diseases</div>
      <div style="font-size: 10pt;"><br>
      </div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">ImmTAAI (Immune mobilizing monoclonal TCRs Against AutoImmune disease) molecules are novel bispecifics that are designed for tissue-specific down modulation of the
      immune system. When tethered to the tissue of interest, ImmTAAI candidates suppress pathogenic T cells via PD1 receptor agonism. The Company is currently advancing two candidates for autoimmune conditions, including Type 1 Diabetes and inflammatory
      dermatological diseases.</div>
    <div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">About PRISM-MEL301 (NCT06112314) &#8211; Phase 3 trial with brenetafusp (IMC-F106C, PRAME-A02) in 1L advanced cutaneous melanoma</div>
      <div style="font-size: 10pt;">&#160;</div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Phase 3 registrational trial is randomizing HLA-A*02:01-positive patients with previously untreated advanced melanoma to brenetafusp + nivolumab versus nivolumab or
      nivolumab + relatlimab, depending on the country where the patient is enrolled. The trial will initially randomize to three arms: two brenetafusp dose regimens (40 mcg and 160 mcg) and control arm. One of the two brenetafusp dose regimens will be
      discontinued after an initial review of the first 60 patients randomized to the two experimental arms (90 patients randomized total). The primary endpoint of the trial is progression free survival (PFS) by blinded independent central review (BICR),
      with secondary endpoints of overall survival (OS) and overall response rate (ORR).</div>
    <div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">About the IMC-F106C-101 Phase 1/2 trial</div>
      <div style="font-size: 10pt;"><br>
      </div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">IMC-F106C-101 is a first-in-human, Phase 1/2 dose escalation trial in patients with multiple solid tumors including non-small cell lung and ovarian cancers. The Phase 1
      dose escalation trial was designed to determine the maximum tolerated dose (MTD), as well as to evaluate the safety, preliminary anti-tumor activity and pharmacokinetics of IMC-F106C (brenetafusp), a bispecific protein built on Immunocore&#8217;s ImmTAC
      technology, and the Company&#8217;s first molecule to target the PRAME antigen. The Company is currently focusing on enrolling patients in combination arms with standards-of-care across multiple tumor types.</div>
    <div>
      <div style="font-size: 10pt;"><br>
      </div>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter">
        <div>
          <div style="font-size: 10pt;">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 33.33%;"><img src="image00003.jpg"></td>
                  <td style="width: 33.33%;"><img src="image00004.jpg"></td>
                  <td style="width: 33.33%; text-align: right; vertical-align: bottom;">
                    <div><br>
                      <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 8pt; font-family: 'Times New Roman';">Page </font><font style="font-size: 8pt;">7</font><font style="font-size: 8pt; font-family: 'Times New Roman';"> of 15 </font></div>
                    </div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div style="width: 100%;" class="BRPFPageHeader">
        <div><img src="image00002.jpg"></div>
      </div>
    </div>
    <div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">About TEBE-AM - Phase 2/3 trial with tebentafusp (gp100xCD3) in second-line or later cutaneous melanoma</div>
      <div style="font-size: 10pt;"><br>
      </div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The trial is randomizing patients with second-line or later advanced cutaneous melanoma who have progressed on an anti-PD1, received prior ipilimumab and, if applicable,
      received a BRAF kinase inhibitor. Patients are randomized to one of three arms including tebentafusp, as monotherapy or in combination with an anti-PD1, and a control arm. The primary endpoint is overall survival.</div>
    <div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">About the ATOM Phase 3 trial</div>
      <div style="font-size: 10pt;"><br>
      </div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The EORTC-led Phase 3 clinical trial will include sites in 10 EU countries and the United States and is randomizing HLA-A*02:01-positive patients with high-risk primary
      uveal melanoma after definitive treatment, by surgery or radiotherapy, and no evidence of metastatic disease on imaging. The trial is expected to enroll a total of 290 patients who will be randomized 1:1 to one of two arms: tebentafusp as monotherapy
      or observation. The primary endpoint of the trial is relapse-free survival (RFS), with secondary objectives of overall survival and safety and tolerability of tebentafusp. Exploratory objectives include the comparison of the health-related quality of
      life between the treatment arms and the evaluation of the role of circulating tumor DNA (ctDNA) as a biomarker for the presence of residual disease.</div>
    <div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">About Uveal Melanoma</div>
      <div style="font-size: 10pt;">&#160;</div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Uveal melanoma is a rare and aggressive form of melanoma, which affects the eye. Although it is the most common primary intraocular malignancy in adults, the diagnosis
      is rare, and up to 50% of people with uveal melanoma will eventually develop metastatic disease. Unresectable or metastatic uveal melanoma typically has a poor prognosis and had no approved treatment until KIMMTRAK.</div>
    <div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">About Cutaneous Melanoma</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Cutaneous melanoma (CM) is the most common form of melanoma. It is the most aggressive skin carcinoma and is associated with the vast majority of skin cancer-related
        mortality. The majority of patients with CM are diagnosed before metastasis but survival remains poor for the large proportion of patients with metastatic disease. Despite recent progress in advanced melanoma therapy, there is still an unmet need
        for new therapies that improve first-line response rates and duration of response as well as for patients who are refractory to first-line treatments.</div>
      <div style="font-size: 10pt;"><br>
      </div>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter">
        <div>
          <div style="font-size: 10pt;">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 33.33%;"><img src="image00003.jpg"></td>
                  <td style="width: 33.33%;"><img src="image00004.jpg"></td>
                  <td style="width: 33.33%; text-align: right; vertical-align: bottom;">
                    <div><br>
                      <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 8pt; font-family: 'Times New Roman';">Page </font><font style="font-size: 8pt;">8</font><font style="font-size: 8pt; font-family: 'Times New Roman';"> of 15 </font></div>
                    </div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div style="width: 100%;" class="BRPFPageHeader">
        <div><img src="image00002.jpg"></div>
      </div>
    </div>
    <div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">About KIMMTRAK<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup></div>
      <div style="font-size: 10pt;">&#160;</div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">KIMMTRAK is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function. KIMMTRAK specifically targets gp100, a
      lineage antigen expressed in melanocytes and melanoma. This is the first molecule developed using Immunocore&#8217;s ImmTAC technology platform designed to redirect and activate T cells to recognize and kill tumor cells. KIMMTRAK has been approved for the
      treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.</div>
    <div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">IMPORTANT SAFETY INFORMATION</div>
      <div style="font-size: 10pt;"><br>
      </div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Cytokine Release Syndrome (CRS), which may be serious or life-threatening, occurred in
        patients receiving KIMMTRAK. Monitor for at least 16 hours following first three infusions and then as clinically indicated.</font><font style="font-size: 10pt;"> Manifestations of CRS may include fever, hypotension, hypoxia, chills, nausea,
        vomiting, rash, elevated transaminases, fatigue, and headache. CRS occurred in 89% of patients who received KIMMTRAK with 0.8% being grade 3 or 4. Ensure immediate access to medications and resuscitative equipment to manage CRS. Ensure patients are
        euvolemic prior to initiating the infusions. Closely monitor patients for signs or symptoms of CRS following infusions of KIMMTRAK. Monitor fluid status, vital signs, and oxygenation level and provide appropriate therapy. Withhold or discontinue
        KIMMTRAK depending on persistence and severity of CRS.</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Skin Reactions</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Skin reactions, including rash, pruritus, and cutaneous edema occurred in 91% of patients treated with KIMMTRAK. Monitor patients for skin reactions. If skin reactions
      occur, treat with antihistamine and topical or systemic steroids based on persistence and severity of symptoms. Withhold or permanently discontinue KIMMTRAK depending on the severity of skin reactions.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Elevated Liver Enzymes</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Elevations in liver enzymes occurred in 65% of patients treated with KIMMTRAK. Monitor alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total blood
      bilirubin prior to the start of and during treatment with KIMMTRAK. Withhold KIMMTRAK according to severity.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter">
        <div>
          <div style="font-size: 10pt;">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 33.33%;"><img src="image00003.jpg"></td>
                  <td style="width: 33.33%;"><img src="image00004.jpg"></td>
                  <td style="width: 33.33%; text-align: right; vertical-align: bottom;">
                    <div><br>
                      <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 8pt; font-family: 'Times New Roman';">Page </font><font style="font-size: 8pt;">9</font><font style="font-size: 8pt; font-family: 'Times New Roman';"> of 15 </font></div>
                    </div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div style="width: 100%;" class="BRPFPageHeader">
        <div><img src="image00002.jpg"></div>
      </div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Embryo-Fetal Toxicity</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">KIMMTRAK may cause fetal harm. Advise pregnant patients of potential risk to the fetus and patients of reproductive potential to use effective contraception during
      treatment with KIMMTRAK and 1 week after the last dose.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The most common adverse reactions (&#8805;30%) in patients who received KIMMTRAK were cytokine release syndrome, rash, pyrexia, pruritus, fatigue, nausea, chills, abdominal
      pain, edema, hypotension, dry skin, headache, and vomiting. The most common (&#8805;50%) laboratory abnormalities were decreased lymphocyte count, increased creatinine, increased glucose, increased AST, increased ALT, decreased hemoglobin, and decreased
      phosphate.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">For more information, please see full Summary of Product Characteristics (SmPC) or full U.S. Prescribing Information (including BOXED WARNING for CRS).</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About KIMMTRAKConnect</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Immunocore is committed to helping patients who need KIMMTRAK obtain access via our KIMMTRAKConnect program. The program provides services with dedicated nurse case
      managers who provide personalized support, including educational resources, financial assistance, and site of care coordination. To learn more, visit KIMMTRAKConnect.com or call 844-775-2273.</div>
    <div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">About Immunocore</div>
      <div style="font-size: 10pt;"><br>
      </div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX &#8211; Immune mobilizing
      monoclonal TCRs Against X disease &#8211; designed to treat a broad range of diseases, including cancer, autoimmune diseases and infectious diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep
      pipeline in multiple therapeutic areas, including numerous active clinical and pre-clinical programs&#8203; in oncology, infectious diseases, and autoimmune diseases. The Company&#8217;s most advanced oncology TCR therapeutic, KIMMTRAK, has been approved for the
      treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.</div>
    <div>
      <div style="font-size: 10pt;"><br>
      </div>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter">
        <div>
          <div style="font-size: 10pt;">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 33.33%;"><img src="image00003.jpg"></td>
                  <td style="width: 33.33%;"><img src="image00004.jpg"></td>
                  <td style="width: 33.33%; text-align: right; vertical-align: bottom;">
                    <div><br>
                      <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 8pt; font-family: 'Times New Roman';">Page </font><font style="font-size: 8pt;">10</font><font style="font-size: 8pt; font-family: 'Times New Roman';"> of 15 </font></div>
                    </div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div style="width: 100%;" class="BRPFPageHeader">
        <div><img src="image00002.jpg"></div>
      </div>
    </div>
    <div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Forward Looking Statements</div>
      <div style="font-size: 10pt;">&#160;</div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">This press release contains &#8220;forward-looking statements&#8221; within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words
      such as &#8220;may&#8221;, &#8220;will&#8221;, &#8220;believe&#8221;, &#8220;expect&#8221;, &#8220;plan&#8221;, &#8220;anticipate&#8221;, &#8220;aim&#8221;, &#8220;continue&#8221;, &#8220;target&#8221; and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking
      statements. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding the Company&#8217;s ability to advance its clinical
      pipeline; the key growth areas for KIMMTRAK, including continued global expansion in mUM, the potential expansion into 2L+ advanced cutaneous melanoma, and into adjuvant uveal melanoma; the commercial performance of KIMMTRAK; the potential benefits
      and advantages that KIMMTRAK will provide for patients; expectations regarding the estimated size of the patient populations for the Company&#8217;s product candidates; expectations regarding the design, progress, timing, enrollment, randomization, scope,
      expansion, funding, and results of the Company&#8217;s existing and planned clinical trials, those of the Company&#8217;s collaboration partners or the combined clinical trials with the Company&#8217;s collaboration partners; the timing and sufficiency of clinical
      trial outcomes to support potential approval of any of the Company&#8217;s product candidates or those of, or combined with, its collaboration partners; the Company&#8217;s goals to develop and commercialize product candidates based on its KIMMTRAK platform
      alone or with collaboration partners; the expected submission of clinical trial applications; and the potential regulatory approval, expected clinical benefits and availability of the Company&#8217;s product candidates. Any forward-looking statements are
      based on management&#8217;s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially and adversely from those set forth in or implied by such
      forward-looking statements, many of which are beyond the Company&#8217;s control. These risks and uncertainties include, but are not limited to, the impact of worsening macroeconomic conditions on the Company&#8217;s business, financial position, strategy and
      anticipated milestones, including Immunocore&#8217;s ability to conduct ongoing and planned clinical trials; Immunocore&#8217;s ability to obtain a clinical supply of current or future product candidates or commercial supply of KIMMTRAK or any future approved
      products; Immunocore&#8217;s ability to obtain and maintain regulatory approval of its product candidates, including KIMMTRAK; Immunocore&#8217;s ability and plans in continuing to establish and expand a commercial infrastructure and to successfully launch,
      market and sell KIMMTRAK and any future approved products; Immunocore&#8217;s ability to successfully expand the approved indications for KIMMTRAK or obtain marketing approval for KIMMTRAK in additional geographies in the future; the delay of any current
      or planned clinical trials, whether due to patient enrollment delays or otherwise; Immunocore&#8217;s ability to successfully demonstrate the safety and efficacy of its product candidates and gain approval of its product candidates on a timely basis, if at
      all; competition with respect to market opportunities; unexpected safety or efficacy data observed during preclinical studies or clinical trials; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials
      or future regulatory approval; Immunocore&#8217;s need for and ability to obtain additional funding, on favorable terms or at all, including as a result of worsening macroeconomic conditions, including changes in inflation and interest rates and
      unfavorable general market conditions, and the impacts thereon of the war in Ukraine, the conflict in the Middle East, and global geopolitical tension; Immunocore&#8217;s ability to obtain, maintain and enforce intellectual property protection for KIMMTRAK
      or any of its product candidates it or its collaborators are developing; and the success of Immunocore&#8217;s current and future collaborations, partnerships or licensing arrangements. These and other risks and uncertainties are described in greater
      detail in the section titled "Risk Factors" in Immunocore&#8217;s filings with the Securities and Exchange Commission, including Immunocore&#8217;s most recent Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange
      Commission on February 26, 2025, as well as discussions of potential risks, uncertainties, and other important factors in the Company&#8217;s subsequent filings with the SEC. All information in this press release is as of the date of the release, and the
      Company undertakes no duty to update this information, except as required by law.</div>
    <div>
      <div style="font-size: 10pt;"><br>
      </div>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter">
        <div>
          <div style="font-size: 10pt;">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 33.33%;"><img src="image00003.jpg"></td>
                  <td style="width: 33.33%;"><img src="image00004.jpg"></td>
                  <td style="width: 33.33%; text-align: right; vertical-align: bottom;">
                    <div><br>
                      <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 8pt; font-family: 'Times New Roman';">Page </font><font style="font-size: 8pt;">11</font><font style="font-size: 8pt; font-family: 'Times New Roman';"> of 15 </font></div>
                    </div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div style="width: 100%;" class="BRPFPageHeader">
        <div><img src="image00002.jpg"></div>
      </div>
    </div>
    <div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Contact Information</div>
      <div style="font-size: 10pt;"><br>
      </div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Immunocore</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">S&#233;bastien Desprez, VP Communications</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">T:<font style="font-family: 'Times New Roman';">&#160;</font>+44 (0) 7458030732</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">E: <font style="font-family: 'Times New Roman';"><u>sebastien.desprez@immunocore.com</u></font></div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Follow Immunocore on LinkedIn: @Immunocore</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Investor Relations</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Clayton Robertson / Morgan Warenius</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">T: +1 (215) 384-4781</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">E: <font style="font-family: 'Times New Roman';"><u>ir@immunocore.com</u></font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter">
        <div>
          <div style="font-size: 10pt;">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 33.33%;"><img src="image00003.jpg"></td>
                  <td style="width: 33.33%;"><img src="image00004.jpg"></td>
                  <td style="width: 33.33%; text-align: right; vertical-align: bottom;">
                    <div><br>
                      <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 8pt; font-family: 'Times New Roman';">Page </font><font style="font-size: 8pt;">12</font><font style="font-size: 8pt; font-family: 'Times New Roman';"> of 15 </font></div>
                    </div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div style="width: 100%;" class="BRPFPageHeader">
        <div><img src="image00002.jpg"></div>
      </div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Immunocore Holdings plc</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Condensed Consolidated Statement of Operations</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Quarter Ended <font style="font-family: 'Times New Roman';">March 31, 2025</font> and <font style="font-family: 'Times New Roman';">2024</font></div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(In thousands, except share and per share data)</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Unaudited)</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="zdb0c1c8c8c474fdc9f8b7322be706513" class="cfttable">

        <tr>
          <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="6">
            <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">Quarter Ended</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; font-size: 10pt;">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt;" colspan="2">
            <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">March 31, </div>
            <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">2025</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt;" colspan="2">
            <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">March 31, </div>
            <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">2024</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Revenue from sale of therapies, net</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">
            <div style="font-family: 'Times New Roman';">$</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">93,881</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">
            <div style="font-family: 'Times New Roman';">$</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">70,342</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; padding-bottom: 2px;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Collaboration revenue</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">&#8212;</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">160</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold;">Total revenue</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">93,881</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">70,502</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Cost of revenue from sale of therapies</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">(831</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="font-family: 'Times New Roman';">)</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">(246</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="font-family: 'Times New Roman';">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Research and development expenses</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">(56,468</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">
            <div style="font-family: 'Times New Roman';">)</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">(57,459</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">
            <div style="font-family: 'Times New Roman';">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; padding-bottom: 2px;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Selling, general, &amp; administrative expenses</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">(40,198</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">
            <div style="font-family: 'Times New Roman';">)</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">(39,287</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">
            <div style="font-family: 'Times New Roman';">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold;">Loss from operations</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">(3,616</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">)</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">(26,490</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Interest income</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">4,176</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">8,246</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Interest expense</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">(3,025</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">
            <div style="font-family: 'Times New Roman';">)</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">(3,239</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">
            <div style="font-family: 'Times New Roman';">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Foreign currency gain (loss)</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">3,080</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">(2,406</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="font-family: 'Times New Roman';">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Other income (expense), net</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">5,469</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">(190</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1" class="cftfncell">
            <div style="font-family: 'Times New Roman';">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold;">Net income (loss) before income taxes</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">6,084</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">(24,079</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Income tax expense</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">(1,061</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">
            <div style="font-family: 'Times New Roman';">)</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">(357</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1" class="cftfncell">
            <div style="font-family: 'Times New Roman';">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; padding-bottom: 2px;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold;">Net income (loss)</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">$</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">5,023</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">$</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">(24,436</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold;">Basic net income (loss) per share</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">$</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">0.10</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">$</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">(0.49</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-style: italic;">Basic weighted-average number of shares outstanding</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">50,086,684</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">49,877,218</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; width: 76%;">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold;">Diluted net income (loss) per share</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">$</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">0.10</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">$</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">(0.49</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-style: italic;">Diluted weighted-average number of shares outstanding</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">51,949,798</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">49,877,218</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter">
        <div>
          <div style="font-size: 10pt;">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 33.33%;"><img src="image00003.jpg"></td>
                  <td style="width: 33.33%;"><img src="image00004.jpg"></td>
                  <td style="width: 33.33%; text-align: right; vertical-align: bottom;">
                    <div><br>
                      <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 8pt; font-family: 'Times New Roman';">Page </font><font style="font-size: 8pt;">13</font><font style="font-size: 8pt; font-family: 'Times New Roman';"> of 15 </font></div>
                    </div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div style="width: 100%;" class="BRPFPageHeader">
        <div><img src="image00002.jpg"></div>
      </div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Immunocore Holdings plc</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Condensed Consolidated Balance Sheets</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">As of</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(In thousands)</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Unaudited)</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="za833dc0dcf0c47d9b7c389d7b0cb9070" class="cfttable">

        <tr>
          <td valign="bottom" style="vertical-align: bottom; font-size: 10pt;">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; border-top: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">March 31, </div>
            <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">2025</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; border-top: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">December 31, 2024</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold;">ASSETS</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; font-size: 10pt;" colspan="2">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; font-size: 10pt;" colspan="2">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold;">Current assets</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; font-size: 10pt;" colspan="2">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; font-size: 10pt;" colspan="2">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Cash and cash equivalents</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">
            <div style="font-family: 'Times New Roman';">$</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">476,845</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">
            <div style="font-family: 'Times New Roman';">$</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">455,731</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Marketable securities</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">360,185</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">364,645</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Accounts receivable, net</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">63,094</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">63,009</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Prepaid expenses and other current assets</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">41,697</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">41,033</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Inventory, net</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">6,804</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">5,446</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold;">Total current assets</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">948,625</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">929,864</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Property and equipment, net</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">9,770</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">10,092</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Operating lease right of use assets, net</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">38,126</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">37,643</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Deferred tax assets, net</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">14,355</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">14,790</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; padding-bottom: 2px;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Other non-current assets</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">17,132</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">17,117</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold;">Total assets</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">$</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">1,028,008</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">$</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">1,009,506</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; width: 76%;">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold;">Liabilities and shareholders&#8217; equity</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold;">Current liabilities</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Accounts payable</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">
            <div style="font-family: 'Times New Roman';">$</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">29,105</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">
            <div style="font-family: 'Times New Roman';">$</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">25,100</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Accrued expenses and other current liabilities</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">118,341</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">185,534</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Operating lease liabilities, current</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">1,717</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">1,547</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold;">Total current liabilities</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">149,163</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">212,181</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Accrued expenses, non-current</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">62,476</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">&#8212;</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Deferred revenue, non-current</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">5,612</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">5,434</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Operating lease liabilities, non-current</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">40,748</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">40,162</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; padding-bottom: 2px;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Interest-bearing loans and borrowings</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">391,530</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">391,013</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold;">Total liabilities</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">$</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">649,529</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">$</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">648,790</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; width: 76%;">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold;">Shareholders' equity</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Ordinary shares</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">135</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">135</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Deferred shares</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">1</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">1</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Additional paid-in capital</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">1,202,171</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">1,190,104</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Accumulated deficit</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">(790,738</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">
            <div style="font-family: 'Times New Roman';">)</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">(795,761</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">
            <div style="font-family: 'Times New Roman';">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; padding-bottom: 2px;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Accumulated other comprehensive loss</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">(33,090</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">
            <div style="font-family: 'Times New Roman';">)</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">(33,763</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">
            <div style="font-family: 'Times New Roman';">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold;">Total shareholders' equity</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">378,479</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">360,716</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; padding-bottom: 2px;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold;">Total liabilities and shareholders' equity</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">$</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">1,028,008</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">$</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">1,009,506</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
        </tr>

    </table>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> </font><font style="font-size: 10pt;"><br>
      </font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter">
        <div>
          <div style="font-size: 10pt;">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 33.33%;"><img src="image00003.jpg"></td>
                  <td style="width: 33.33%;"><img src="image00004.jpg"></td>
                  <td style="width: 33.33%; text-align: right; vertical-align: bottom;">
                    <div><br>
                      <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 8pt; font-family: 'Times New Roman';">Page </font><font style="font-size: 8pt;">14</font><font style="font-size: 8pt; font-family: 'Times New Roman';"> of 15 </font></div>
                    </div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div style="width: 100%;" class="BRPFPageHeader">
        <div><img src="image00002.jpg"></div>
      </div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Immunocore Holdings plc</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Summary Condensed Consolidated Statements of Cash Flows</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">For the Quarter Ended <font style="font-family: 'Times New Roman';">March 31,</font></div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(In thousands)</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Unaudited)</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="z17034f8cb44344cc8f5d92a2d89887b5" class="cfttable">

        <tr>
          <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;"> 2025</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">2024</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; font-size: 10pt;">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; font-size: 10pt;" colspan="2">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; font-size: 10pt;" colspan="2">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Cash and cash equivalents at beginning of period</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">
            <div style="font-family: 'Times New Roman';">$</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">455,731</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">
            <div style="font-family: 'Times New Roman';">$</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">442,626</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Net cash provided by (used in) operating activities</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">435</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">(4,587</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="font-family: 'Times New Roman';">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Net cash provided by (used in) investing activities</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">9,702</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">(430</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">
            <div style="font-family: 'Times New Roman';">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Net cash provided by financing activities</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">2,551</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">396,012</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Net foreign exchange difference on cash held</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">8,426</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman';">(800</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1" class="cftfncell">
            <div style="font-family: 'Times New Roman';">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 76%; padding-bottom: 2px;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold;">Cash and cash equivalents at end of period</div>
          </td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">$</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">476,845</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">$</div>
          </td>
          <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">832,821</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter">
        <div>
          <div style="font-size: 10pt;">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 33.33%;"><img src="image00003.jpg"></td>
                  <td style="width: 33.33%;"><img src="image00004.jpg"></td>
                  <td style="width: 33.33%; text-align: right; vertical-align: bottom;">
                    <div><br>
                      <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 8pt; font-family: 'Times New Roman';">Page </font><font style="font-size: 8pt;">15</font><font style="font-size: 8pt; font-family: 'Times New Roman';"> of 15 </font></div>
                    </div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
    </div>
    <div style="font-size: 10pt;">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
  <font style="font-size: 10pt;"> </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>imcr-20250507.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.3.2.5298 Broadridge-->
<xs:schema targetNamespace="http://immunocore.com./20250507" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:imcr="http://immunocore.com./20250507" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:srt-types="http://fasb.org/srt-types/2024">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="imcr-20250507_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="imcr-20250507_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="imcr-20250507_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://immunocore.com./role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2024" schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/cyd/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" />
  <xs:element name="OrdinaryShareNominalValueGBP0002PerShareMember" id="imcr_OrdinaryShareNominalValueGBP0002PerShareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>imcr-20250507_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.3.2.5298 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:t1="http://xbrl.org/2005/xbrldt">
  <link:roleRef roleURI="http://immunocore.com./role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="imcr-20250507.xsd#DocumentAndEntityInformation" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://immunocore.com./role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityListingsLineItems" xlink:label="EntityListingsLineItems" xlink:title="EntityListingsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="DocumentType" xlink:title="definition: EntityListingsLineItems to DocumentType" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="AmendmentFlag" xlink:title="definition: EntityListingsLineItems to AmendmentFlag" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="DocumentPeriodEndDate" xlink:title="definition: EntityListingsLineItems to DocumentPeriodEndDate" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="DocumentFiscalYearFocus" xlink:title="definition: EntityListingsLineItems to DocumentFiscalYearFocus" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="DocumentFiscalPeriodFocus" xlink:title="definition: EntityListingsLineItems to DocumentFiscalPeriodFocus" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityFileNumber" xlink:title="definition: EntityListingsLineItems to EntityFileNumber" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityRegistrantName" xlink:title="definition: EntityListingsLineItems to EntityRegistrantName" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityCentralIndexKey" xlink:title="definition: EntityListingsLineItems to EntityCentralIndexKey" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityIncorporationStateCountryCode" xlink:title="definition: EntityListingsLineItems to EntityIncorporationStateCountryCode" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityTaxIdentificationNumber" xlink:title="definition: EntityListingsLineItems to EntityTaxIdentificationNumber" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine1" xlink:title="definition: EntityListingsLineItems to EntityAddressAddressLine1" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine2" xlink:title="definition: EntityListingsLineItems to EntityAddressAddressLine2" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine3" xlink:title="definition: EntityListingsLineItems to EntityAddressAddressLine3" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressCityOrTown" xlink:title="definition: EntityListingsLineItems to EntityAddressCityOrTown" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressStateOrProvince" xlink:title="definition: EntityListingsLineItems to EntityAddressStateOrProvince" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressCountry" xlink:title="definition: EntityListingsLineItems to EntityAddressCountry" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressPostalZipCode" xlink:title="definition: EntityListingsLineItems to EntityAddressPostalZipCode" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="CityAreaCode" xlink:title="definition: EntityListingsLineItems to CityAreaCode" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="LocalPhoneNumber" xlink:title="definition: EntityListingsLineItems to LocalPhoneNumber" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="Security12bTitle" xlink:title="definition: EntityListingsLineItems to Security12bTitle" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="TradingSymbol" xlink:title="definition: EntityListingsLineItems to TradingSymbol" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="NoTradingSymbolFlag" xlink:title="definition: EntityListingsLineItems to NoTradingSymbolFlag" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="SecurityExchangeName" xlink:title="definition: EntityListingsLineItems to SecurityExchangeName" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityEmergingGrowthCompany" xlink:title="definition: EntityListingsLineItems to EntityEmergingGrowthCompany" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="WrittenCommunications" xlink:title="definition: EntityListingsLineItems to WrittenCommunications" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="SolicitingMaterial" xlink:title="definition: EntityListingsLineItems to SolicitingMaterial" order="26.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="PreCommencementTenderOffer" xlink:title="definition: EntityListingsLineItems to PreCommencementTenderOffer" order="27.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="definition: EntityListingsLineItems to PreCommencementIssuerTenderOffer" order="28.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityListingsTable" xlink:label="EntityListingsTable" xlink:title="EntityListingsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="EntityListingsLineItems" xlink:to="EntityListingsTable" xlink:title="definition: EntityListingsLineItems to EntityListingsTable" order="29.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="EntityListingsTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: EntityListingsTable to StatementClassOfStockAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="CommonStockMember" xlink:title="definition: ClassOfStockDomain to CommonStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="imcr-20250507.xsd#imcr_OrdinaryShareNominalValueGBP0002PerShareMember" xlink:label="OrdinaryShareNominalValueGBP0002PerShareMember" xlink:title="OrdinaryShareNominalValueGBP0002PerShareMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="OrdinaryShareNominalValueGBP0002PerShareMember" xlink:title="definition: ClassOfStockDomain to OrdinaryShareNominalValueGBP0002PerShareMember" order="2.0" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>imcr-20250507_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.3.2.5298 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockMember" xml:lang="en-US" id="us-gaap_CommonStockMember">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="us-gaap_CommonStockMember" xlink:title="label: CommonStockMember to us-gaap_CommonStockMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfStockDomain" xml:lang="en-US" id="us-gaap_ClassOfStockDomain">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain" xlink:title="label: ClassOfStockDomain to us-gaap_ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementClassOfStockAxis" xml:lang="en-US" id="us-gaap_StatementClassOfStockAxis">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:title="label: StatementClassOfStockAxis to us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract" xml:lang="en-US" id="dei_CoverAbstract">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract" xlink:title="label: CoverAbstract to dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType" xml:lang="en-US" id="dei_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType" xlink:title="label: DocumentType to dei_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications" xml:lang="en-US" id="dei_WrittenCommunications">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications" xlink:title="label: WrittenCommunications to dei_WrittenCommunications" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial" xml:lang="en-US" id="dei_SolicitingMaterial">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer" xml:lang="en-US" id="dei_PreCommencementTenderOffer">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag" xml:lang="en-US" id="dei_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag" xlink:title="label: AmendmentFlag to dei_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus" xml:lang="en-US" id="dei_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate" xml:lang="en-US" id="dei_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName" xml:lang="en-US" id="dei_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey" xml:lang="en-US" id="dei_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber" xml:lang="en-US" id="dei_EntityFileNumber">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber" xlink:title="label: EntityFileNumber to dei_EntityFileNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1" xml:lang="en-US" id="dei_EntityAddressAddressLine1">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2" xml:lang="en-US" id="dei_EntityAddressAddressLine2">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3" xml:lang="en-US" id="dei_EntityAddressAddressLine3">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown" xml:lang="en-US" id="dei_EntityAddressCityOrTown">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince" xml:lang="en-US" id="dei_EntityAddressStateOrProvince">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry" xml:lang="en-US" id="dei_EntityAddressCountry">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode" xml:lang="en-US" id="dei_EntityAddressPostalZipCode">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode" xml:lang="en-US" id="dei_CityAreaCode">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode" xlink:title="label: CityAreaCode to dei_CityAreaCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber" xml:lang="en-US" id="dei_LocalPhoneNumber">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityListingsTable" xlink:label="EntityListingsTable" xlink:title="EntityListingsTable" />
    <link:label xlink:type="resource" xlink:label="dei_EntityListingsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityListingsTable" xml:lang="en-US" id="dei_EntityListingsTable">Entity Listings [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityListingsTable" xlink:to="dei_EntityListingsTable" xlink:title="label: EntityListingsTable to dei_EntityListingsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityListingsLineItems" xlink:label="EntityListingsLineItems" xlink:title="EntityListingsLineItems" />
    <link:label xlink:type="resource" xlink:label="dei_EntityListingsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityListingsLineItems" xml:lang="en-US" id="dei_EntityListingsLineItems">Entity Listings [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityListingsLineItems" xlink:to="dei_EntityListingsLineItems" xlink:title="label: EntityListingsLineItems to dei_EntityListingsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle" xml:lang="en-US" id="dei_Security12bTitle">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle" xlink:title="label: Security12bTitle to dei_Security12bTitle" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag" xml:lang="en-US" id="dei_NoTradingSymbolFlag">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol" xml:lang="en-US" id="dei_TradingSymbol">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol" xlink:title="label: TradingSymbol to dei_TradingSymbol" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName" xml:lang="en-US" id="dei_SecurityExchangeName">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName" />
    <link:loc xlink:type="locator" xlink:href="imcr-20250507.xsd#imcr_OrdinaryShareNominalValueGBP0002PerShareMember" xlink:label="OrdinaryShareNominalValueGBP0002PerShareMember" xlink:title="OrdinaryShareNominalValueGBP0002PerShareMember" />
    <link:label xlink:type="resource" xlink:label="imcr_OrdinaryShareNominalValueGBP0002PerShareMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="imcr_OrdinaryShareNominalValueGBP0002PerShareMember_lbl1" xml:lang="en-US" id="imcr_OrdinaryShareNominalValueGBP0002PerShareMember_lbl1">Ordinary share, nominal value GBP 0.002 per share* [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrdinaryShareNominalValueGBP0002PerShareMember" xlink:to="imcr_OrdinaryShareNominalValueGBP0002PerShareMember_lbl1" xlink:title="label: OrdinaryShareNominalValueGBP0002PerShareMember to imcr_OrdinaryShareNominalValueGBP0002PerShareMember_lbl1" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>imcr-20250507_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.3.2.5298 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://immunocore.com./role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="imcr-20250507.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://immunocore.com./role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityListingsTable" xlink:label="EntityListingsTable" xlink:title="EntityListingsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="CommonStockMember" xlink:title="presentation: ClassOfStockDomain to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="imcr-20250507.xsd#imcr_OrdinaryShareNominalValueGBP0002PerShareMember" xlink:label="OrdinaryShareNominalValueGBP0002PerShareMember" xlink:title="OrdinaryShareNominalValueGBP0002PerShareMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="OrdinaryShareNominalValueGBP0002PerShareMember" xlink:title="presentation: ClassOfStockDomain to OrdinaryShareNominalValueGBP0002PerShareMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: EntityListingsTable to StatementClassOfStockAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityListingsLineItems" xlink:label="EntityListingsLineItems" xlink:title="EntityListingsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="DocumentType" xlink:title="presentation: EntityListingsLineItems to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="AmendmentFlag" xlink:title="presentation: EntityListingsLineItems to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: EntityListingsLineItems to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: EntityListingsLineItems to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: EntityListingsLineItems to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityFileNumber" xlink:title="presentation: EntityListingsLineItems to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityRegistrantName" xlink:title="presentation: EntityListingsLineItems to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityCentralIndexKey" xlink:title="presentation: EntityListingsLineItems to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: EntityListingsLineItems to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: EntityListingsLineItems to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: EntityListingsLineItems to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: EntityListingsLineItems to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: EntityListingsLineItems to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: EntityListingsLineItems to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: EntityListingsLineItems to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressCountry" xlink:title="presentation: EntityListingsLineItems to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: EntityListingsLineItems to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="CityAreaCode" xlink:title="presentation: EntityListingsLineItems to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="LocalPhoneNumber" xlink:title="presentation: EntityListingsLineItems to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="Security12bTitle" xlink:title="presentation: EntityListingsLineItems to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="TradingSymbol" xlink:title="presentation: EntityListingsLineItems to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: EntityListingsLineItems to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="SecurityExchangeName" xlink:title="presentation: EntityListingsLineItems to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: EntityListingsLineItems to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="WrittenCommunications" xlink:title="presentation: EntityListingsLineItems to WrittenCommunications" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="SolicitingMaterial" xlink:title="presentation: EntityListingsLineItems to SolicitingMaterial" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: EntityListingsLineItems to PreCommencementTenderOffer" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: EntityListingsLineItems to PreCommencementIssuerTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsTable" xlink:to="EntityListingsLineItems" xlink:title="presentation: EntityListingsTable to EntityListingsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityListingsTable" xlink:title="presentation: CoverAbstract to EntityListingsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image00002.jpg
<TEXT>
begin 644 image00002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  8 .<# 2(  A$! Q$!_\0
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/_P#LJ***V^H43+ZU4/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image00003.jpg
<TEXT>
begin 644 image00003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  W 'P# 2(  A$! Q$!_\0
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M7RS9JHWPA8V8AR?XCM^G3'K5R/Q6[SQVW]G.+V9D\J(RC#(R[MQ;'&!VI-U
M2@3>%=-OM)+PSQPB&8F0B-LB,X   P!S@D\"NCKAKCQC+>V,4^GVSPH)+<3R
MLZDQ[R#MQW^7N/6KJ^,-WDA-/DWW)0VJ^:/WB.6 8G'R_=Z<U$J<V[M%1G%:
M(ZRBN?T/Q'_:=U%"]G);^;$TD99PV2K;6!QTP?SKH*S<7%V9::>J*.H:1I^H
MRQR7UI#.\?"LZY('7'TI5TNQ50!;1C$WV@8'23^]]:**+L+(4:99"WC@%M%Y
M,;B1$V\*P.<U-<6L%SY?GQ(_EN)$W#.&'0T447861 NE6*+"J6T:B%&CCP,;
M5;J![&G0:=;6\\<L$8C\N+R45> JYS@"BBB["R*\>@:5&\[)86ZM,,283J,Y
MQ^?-2RZ1I\LDKRVD+M*I5R5SN! !S^"C\J**.9]PLB)-!TM9#(+&#>4\LDKG
M*XQC\N*=:Z)IMK;SP6]G#'%.,2J%X<8QS^%%%',^X60ZXT?3[B4R36D3N5"D
ME>H (&?P)'XU3UKP];W\*"'RX)5*G<8@X(48 (/IGBBBFI- XIB6'A;2K6WL
MXS:QS26J*B2NHW?+R#^!JW!H>F6\C/!90(QD$A*KCYAG!_4_G110Y2>[#E78
:GM].M+>1'@MXT:,,%('0,<G\S5JBBIN,_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image00004.jpg
<TEXT>
begin 644 image00004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  Z )8# 2(  A$! Q$!_\0
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+PHHHJ1A1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>May 07, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  07,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39992<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Immunocore Holdings plc<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001671927<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">X0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">92 Park Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Milton Park, Abingdon<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Oxfordshire<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">GB<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">OX14 4RY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">1235 438600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares, each representing one ordinary share, nominal value &#163;0.002 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IMCR<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=imcr_OrdinaryShareNominalValueGBP0002PerShareMember', window );">Ordinary share, nominal value GBP 0.002 per share* [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary share, nominal value &#163;0.002 per share*<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">*<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imcr_OrdinaryShareNominalValueGBP0002PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imcr_OrdinaryShareNominalValueGBP0002PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( #P\IUI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( #P\IUI_MSL1\@   "L"   1
M9&]C4')O<',O8V]R92YX;6S-DE%+PS 0Q[^*Y+V]IF4;A"XOBD\*@@/%MY#<
MMF#3A.2DW;<WK5NGZ <0\I*[?W[W.TBK@] ^XE/T 2-93#>CZ_HD=-BR(U$0
M $D?T:E4YD2?FWL?G:)\C0<(2K^K T)=56MP2,HH4C !B[ 0F6R-%CJB(A_/
M>*,7?/B(W0PS&K!#ASTEX"4')J>)X31V+5P!$XPPNO150+,0Y^J?V+D#[)P<
MDUU2PS"40S/G\@X<7A\?GN=U"]LG4KW&_"I90:> 6W:9_-+<WNWNF:RK>E54
M^6QVG(NF$:OUV^3ZP^\J[+RQ>_O/C#??C"^"LH5?_T)^ E!+ P04    "  \
M/*=:F5R<(Q &  "<)P  $P   'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4
M?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.'X416(UL>621A'^_1S80RY8-[9)-
MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( #P\IUKXUOSC% 4  #@6   8
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MNX"6\]&<CV9RM0-R.Z0[H8U(YII\O8,!9&!XK/\M@]NJU<O5;(I?Z)0%O.-
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M&?BK'0"_SZ0T+R?V;6/^LKC['U!+ P04    "  \/*=:GZ ;\+$"  #B#
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M#ZP+V.Q _G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X
M%F>0IA@"IQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04    "  \/*=:
MEXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S
M9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X
M 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO
M3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)
MTZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0
M   ( #P\IUH<.&7J/P$  #P"   /    >&PO=V]R:V)O;VLN>&ULC5'+;L)
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MPNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    "  \/*=:1L=-2)4   #-
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M #P\IUI_MSL1\@   "L"   1              "  <,   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( #P\IUJ97)PC$ 8  )PG   3
M  "  >0!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ /#RG6OC6
M_.,4!0  .!8  !@              ("!)0@  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( #P\IUJ?H!OPL0(  .(,   -
M  "  6\-  !X;"]S='EL97,N>&UL4$L! A0#%     @ /#RG6I>*NQS
M$P(   L              ( !2Q   %]R96QS+RYR96QS4$L! A0#%     @
M/#RG6APX9>H_ 0  / (   \              ( !-!$  'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( #P\IUHD'INBK0   /@!   :              "
M : 2  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( #P\
MIUIED'F2&0$  ,\#   3              "  843  !;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@     )  D /@(  ,\4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ef20048471_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immunocore.com./role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ef20048471_8k.htm">ef20048471_8k.htm</File>
    <File>imcr-20250507.xsd</File>
    <File>imcr-20250507_def.xml</File>
    <File>imcr-20250507_lab.xml</File>
    <File>imcr-20250507_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="26">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ef20048471_8k.htm": {
   "nsprefix": "imcr",
   "nsuri": "http://immunocore.com./20250507",
   "dts": {
    "inline": {
     "local": [
      "ef20048471_8k.htm"
     ]
    },
    "schema": {
     "local": [
      "imcr-20250507.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "imcr-20250507_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "imcr-20250507_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "imcr-20250507_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 1,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 35,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 26
   },
   "report": {
    "R1": {
     "role": "http://immunocore.com./role/DocumentAndEntityInformation",
     "longName": "000100 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c20250507to20250507",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20048471_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250507to20250507",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20048471_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "imcr_OrdinaryShareNominalValueGBP0002PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immunocore.com./20250507",
     "localname": "OrdinaryShareNominalValueGBP0002PerShareMember",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary share, nominal value GBP 0.002 per share* [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001140361-25-017615-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-25-017615-xbrl.zip
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M!'@%F$PE\?L-<#9![IOIF$US_P,X-Q#T%LL^4OLZ<$D*.PY\#U&QX \F$V1
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MFQG,S9AO4FQ&4SY6G[V\'^_]/U!+ P04    "  \/*=:H*6!!\%'  "^.0,
M%0   &5F,C P-#@T-S%?97@Y.2TQ+FAT;>U]:7?;2+;8]YR3_U!1+T_*@#1
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MT^;"'XT$MQW'&76]3E\,[ ;\=P[\?R]@O6*476>'95X"^F>$(2#:BNPI7#!
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M-J##>3<_QJ#&;A[RY*"T ]V<@7\'LC7B=M^R^T/./6Z;?6<TXKU1M]OCOG!
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MX7,R'&J)\9$RL&JMJNB]ZW)B\S%@A=,3M5U0=H5LJ5.F&RUD88'VK"H,+2<
MK<CZ*2:?KV5*#M"4D8T6E))2?8X$$BGE#T5CAK)$P@*EF.1>:0FF%#UU:&89
MVE%X6Y7.@@G6Y#Y=Z]%=V?-]95H7:7@RU4D4T6FK,[ND J^RNHJC0+W'00-!
MH> H&;/P*L^%C*XR29&RMR!^YK=6P5;G7LND<;A6>(Z93$<\XAXHK(<Y!CZ%
M 3<6[6C_A!/UXNE6J&'')U^_G)X??CYG9X<?WI__7W;\^<.7TY/#\^,OG[?
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M?*4H/&4+JX"2U#YEWK;J\G2[RY2;DV=B$"W3N\1=&1)/K]G&X@SCF,L(9YT
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MA_ _Q:;=4/"$-C)YQ:8\&0=1"_B>/@+U1(=%JPGU4JO+TD=@FG0(\_-^B&/
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M<Q?Z;S?(TB#+ _#LFK:4WOE:)QOBV'X0\<BM'Y^N,7VI+Q%Y3$K1,7J].AJ
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M=KH$!-[BD'T)_@+!&G[Y-.GU>NX$DJ3(R&N_G44C5-VYD:0/:H'B;E U?':
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MTJ;ZQ@_IK?,T43Y9G.!,;TY>V;D\T6K\8%^(MF]A/]@7B'WX'U!+ 0(4 Q0
M   ( #P\IUKK_G@Z=10  ,:*   1              "  0    !E9C(P,#0X
M-#<Q7SAK+FAT;5!+ 0(4 Q0    ( #P\IUJ@I8$'P4<  +XY P 5
M      "  :04  !E9C(P,#0X-#<Q7V5X.3DM,2YH=&U02P$"% ,4    "  \
M/*=:[3EZMM4#  ")$0  $0              @ &87   :6UC<BTR,#(U,#4P
M-RYX<V102P$"% ,4    "  \/*=:=:O70OP&    10  %0
M@ &<8   :6UC<BTR,#(U,#4P-U]D968N>&UL4$L! A0#%     @ /#RG6GA!
M[B4X"@  YV<  !4              ( !RV<  &EM8W(M,C R-3 U,#=?;&%B
M+GAM;%!+ 0(4 Q0    ( #P\IUK 7*(7!@<  (M-   5              "
M 39R  !I;6-R+3(P,C4P-3 W7W!R92YX;6Q02P4&      8 !@"* 0  ;WD
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>ef20048471_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:imcr="http://immunocore.com./20250507"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="imcr-20250507.xsd" xlink:type="simple"/>
    <context id="c20250507to20250507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671927</identifier>
        </entity>
        <period>
            <startDate>2025-05-07</startDate>
            <endDate>2025-05-07</endDate>
        </period>
    </context>
    <context id="c20250507to20250507_StatementClassOfStockAxis_OrdinaryShareNominalValueGBP0002PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imcr:OrdinaryShareNominalValueGBP0002PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-07</startDate>
            <endDate>2025-05-07</endDate>
        </period>
    </context>
    <context id="c20250507to20250507_StatementClassOfStockAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-07</startDate>
            <endDate>2025-05-07</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20250507to20250507"
      id="Fact_ecc1db2c3367422f97892b3e3fe3b170">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20250507to20250507"
      id="Fact_0ac1a0787d654b5d909ba3f7b67f0b32">0001671927</dei:EntityCentralIndexKey>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20250507to20250507"
      id="Fact_c6eda689bea14232ab6026f85bd34936">00-0000000</dei:EntityTaxIdentificationNumber>
    <dei:DocumentType
      contextRef="c20250507to20250507"
      id="Fact_aa2ed1e62dd441ffbea5264fa13ea5ee">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20250507to20250507"
      id="Fact_8ec9d7f294884306834e7be27c17dc0a">2025-05-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20250507to20250507"
      id="Fact_a784e4a95ea64e59bde367bacef7fd96">Immunocore Holdings plc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20250507to20250507"
      id="Fact_7df24f49abc94bfb8880431cd56774d7">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20250507to20250507"
      id="Fact_96bbc3cf5f854d0eb83147d36d4c2416">001-39992</dei:EntityFileNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20250507to20250507"
      id="Fact_6fb2b60cb0354d88bba7c65a3545e940">92 Park Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="c20250507to20250507"
      id="Fact_63c885967ef94e6e9acbb0e3bba169f2">Milton Park, Abingdon</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="c20250507to20250507"
      id="Fact_a1df8faf64e144d4b30273a0316f8701">Oxfordshire</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="c20250507to20250507"
      id="Fact_8813a03ca49540b7a1a4e614977b25b3">GB</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode
      contextRef="c20250507to20250507"
      id="Fact_63b6d4f8c9d94fbb99440606fee1da25">OX14 4RY</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20250507to20250507"
      id="Fact_6cf8d955604448c3beb7d9872d2debd6">44</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20250507to20250507"
      id="Fact_b00d58703c65477ea456f6b922bec8b5">1235 438600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20250507to20250507"
      id="Fact_d057cdeac33b40eda5fa5c5529236e22">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20250507to20250507"
      id="Fact_6f7a140323cc4fb2a527b2be5880438e">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20250507to20250507"
      id="Fact_64cf1fb6fd994deaac996b45a57c5f80">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20250507to20250507"
      id="Fact_519e5e39b11142a494941b20cf97541f">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20250507to20250507_StatementClassOfStockAxis_CommonStockMember"
      id="Fact_4b1113f9c694496ba3cc7bf3d6471a38">American Depositary Shares, each representing one ordinary share, nominal value &#xa3;0.002 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20250507to20250507_StatementClassOfStockAxis_CommonStockMember"
      id="Fact_357d4262392d414b985164d2afb7f1ab">IMCR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20250507to20250507_StatementClassOfStockAxis_CommonStockMember"
      id="Fact_4a9bd6cf21cf49ee92b54ef1ec79c4c6">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="c20250507to20250507_StatementClassOfStockAxis_OrdinaryShareNominalValueGBP0002PerShareMember"
      id="Fact_76b778887af648cb884153225e062dcc">Ordinary share, nominal value &#xa3;0.002 per share*</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20250507to20250507_StatementClassOfStockAxis_OrdinaryShareNominalValueGBP0002PerShareMember"
      id="Fact_230b79239d4947acad3c90ba4660e297">*</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20250507to20250507_StatementClassOfStockAxis_OrdinaryShareNominalValueGBP0002PerShareMember"
      id="Fact_8bfcc247a31b44c78a9618a5ec82ae2d">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20250507to20250507"
      id="Fact_099328ba678b4a6eb3cbfe0540fea9b6">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
